John F. DiPersio, MD, PhD

John F. DiPersio, MD, PhD

Virginia E and Sam J Golman Professor; Section Director – Cellular Therapy

Address:
Division of Oncology
Mail Stop 8007-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110

11th Floor Mid Campus Center (office)

626 Southwest Tower (lab)

Admin:
Cathy Wiggins
cwiggins@wustl.edu

Biosketch

Education

  • 1980: MD/PhD in Microbiology, University of Rochester, Rochester, NY
  • 1973: BA in Biology (Magna Cum Laude), Williams College, Williamstown, MA

Post-Graduate Training

  • 1987-1984: Fellow, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA
  • 1984-1983: Chief Resident, Parkland Memorial Hospital, UT Southwestern, Dallas, TX
  • 1983-1981: Resident, Parkland Memorial Hospital, UT Southwestern, Dallas, TX
  • 1981-1980: Intern (Straight Medicine), Parkland Memorial Hospital, UT Southwestern, Dallas, TX

Academic Positions

  • present-2017: Director, Center for Gene and Cellular Immunotherapy (CGCI), Washington University School of Medicine, St. Louis, MO
  • present-1997: Professor of Medicine, Pediatrics and Pathology/Immunology, Washington University School of Medicine, St. Louis, MO
  • 2022-2000: Chief, Division of Oncology, Washington University School of Medicine, St. Louis, MO
  • 2022-2000: Deputy Director, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • 2000-1997: Acting Director, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • 2000-1994: Chief, Division of Bone Marrow Transplantation & Stem Cell Biology, Washington University School of Medicine, St. Louis, MO
  • 1994-1990: Director, Bone Marrow Transplant Program, Strong Memorial Hospital, Rochester, NY
  • 1994-1990: Assistant Professor of Medicine, Hematology Unit, University of Rochester School of Medicine, Rochester, NY
  • 1997-1994: Associate Professor of Medicine, Pediatrics and Pathology, Washington University School of Medicine, St. Louis, MO
  • 2011-2006: Scientific Director, Good Manufacturing Procedure (GMP) Facility, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • 2006-2000: Director, Section of Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, St. Louis, MO
  • 1994-1990: Assistant Professor of Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY
  • 1990-1988: Assistant Professor of Medicine, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA
  • 1988-1987: Instructor of Medicine, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA

Board Certification

  • 1988: American Board of Internal Medicine (Hematology)
  • 1987: American Board of Internal Medicine (Medical Oncology)
  • 1984: American Board of Internal Medicine

Other Experience & Professional Memberships

  • present-2024: Member, EAB MD Anderson Institute for Cell Therapy Discovery & Innovation
  • present-2024: Member LLS SCOR Study Section
  • present-2023: Member, AACR Cancer Immunology Working Group Steering Committee
  • present-2020: Member EAB Mt. Sinai PPD in Stem Cell Transplantation
  • present-2020: Member EAB O’Neal CCC at University of Alabama at Birmingham
  • present-2020: Member EAB Case CCC
  • present-2020: Member EAB DFCI Department of Medical Oncology
  • present-2019: Member Dana Farber Cancer Institute (DFCI) External Advisory Board
  • present-2019: Member EAB of DFCI Leukemia SPORE
  • present-2019: Member EAB of MSKCC Leukemia SPORE
  • present-2018: EAB member, University of Rochester
  • present-2018: EAB member, Weill Cornell Medicine
  • present-2018: Member AACR Honorific Awards Committee
  • present-2015: EAB member, Sylvester Comprehensive Cancer Center, University of Miami
  • present-2014: EAB member, University of Chicago
  • present-2012: NIH Study Section for Loan Repayment Program
  • present-2012: EAB member, University of Michigan Cancer Center
  • 2024: Chair, UCSD Hematology-Oncology External Review panel
  • 2022: FDA, Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)
  • 2022: Member, AACR Task Force of Hematologic Malignancies
  • 2022: Chair, AACR Hematologic Malignancies Research Grants Scientific Review Committee
  • 2021-2017: Member, ASH Honorific Award and ASH Mentor Award Committee
  • 2021: City of Hope National Medical Center CCC EAB Member
  • 2019-2017: Chair, for the Finneran Prize Awardee, MDACC
  • 2019-2016: Member, AACR Science Policy and Government Affairs Committee (SPGAC)
  • 2019-2014: Study Section Member CPRIT (Cancer Prevention Research Institute of Texas)
  • 2019-2013: Member, Board of Scientific Councilors, National Cancer Institute (NCI)
  • 2019: Member Scientific Committee, 2019 Acute Leukemias SVII, Munich Germany
  • 2018: Leukemia and Lymphoma Society New Idea Award Committee
  • 2018: NIH/NCI Cancer Moonshot Human Tumor Atlas Study Section ZRG1 OTC-T
  • 2018: EAB member, DFCI Leukemia SPORE
  • 2017-2015: Member, AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research Scientific Research Committee
  • 2017: Review Committee Member, NIH Pioneer Award
  • 2016: Chair, Data Safety Monitoring Committee (DSMC) BL-8040 and Nivolumb for the Treatment of Pancreatic Cancer
  • 2016: Chair, DSMC Dana Farber/Boston Childrens Hospital “Use of Plerixafor for Stem Cell Mobilization in Patients with Sickle Cell Disease”
  • 2015: American Cancer Society, National Board of Directors for Hope Lodges
  • 2015: Medical Advisory Board, Gabrielle’s Angel Foundation for Cancer Research
  • 2014-2012: Vice Chair (2012-13) and Chair (2013-14) ASH Scientific Committee on Hematopoiesis
  • 2014: CIRM Working Group 2.0 – Permanent Member
  • 2013: Member, NCI Provocative Questions B Study Section
  • 2013: EAB member, Levine Cancer Institute
  • 2012-2007: Co-Chair, CIBMTR Acute Leukemia Working Committee
  • 2011-2008 Member, Scientific and Medical Research Funding; California Institute for Regenerative Medicine (CIRM)
  • 2011: NIH (BST-M)/CSR- Special Emphasis Panel
  • 2011: Study Section, Doris Duke Center Grants for Sickle Cell Disease
  • 2011: Chairman, NIH/NIDDK P01 Special Emphasis Panel, Methylation and Hematopoiesis
  • 2010: ASH/CRTI Faculty/Mentor
  • 2010: Member, External Advisory Board, Cancer Therapy and Research Center, UT San Antonio
  • 2010: Chairman, NIH NIAID ZAI1 MFH-01 P01 Special Emphasis Panel
  • 2009-2004: NCI (NIH) Permanent member CONC Study Section Member
  • 2009: Member, Review Panel; Center Grants, National Medical Research Council, Singapore
  • 2009: Member, ASBMT Committee on Research Priorities
  • 2008: NCI P01 Special Emphasis Panel ZCA1-RPRB-J, October 2008, Bethesda MD
  • 2008: ASH Scientific Committees on Cell and Gene Therapy and Hematopoiesis
  • 2006-1999: Member, External Advisory Panel, M.D. Anderson, (MDACC) PPG-AML
  • 2006-2003: Award Member, ASH Committee on Educational Affairs, Washington, DC
  • 2006-2003: Member, Board of Directors, American Society of Biology and Marrow Transplant
  • 2006-2000: Leukemia and Lymphoma Society of America, Career Development Award Study Section Member
  • 2006: NIH (ZRG)/CSR – Gene Therapy and Inborn Errors – Special Emphasis Review Panel
  • 2005: Chairman, Study Section RFA HL-04-017 (NHLBI) Specialized Center for Cell Based Therapy
  • 2002: Member, Executive Committee IBMTR/ABMTR
  • 2000: Chairman, NHLBI Consensus Conference on Allo Transplantation for Non-Malignant Diseases
  • 1998: Member, Barnard Free Skin and Cancer Board of Directors
  • 1998: Guest Editor, Blood Journal
  • 1999: Deputy Director, Siteman Cancer Center, Washington University School of Medicine
  • 1997: Chairman, Nominating Committee, International Society for Experimental Hematology (ISEH)
  • 1997: Member, Stem Cell Evaluation Committee, International Society for Hematotherapy and Graft Engineering (ISHAGE)
  • 1997: Councilor, International Society of Experimental Hematology
  • 1995: Member, Nominating Committee, International Society for Experimental Hematology
  • 1993: Member, Editorial Board, Journal of Experimental Hematology

Honors

  • 2025: President, Society of Hematologic Oncology (SOHO)
  • 2024-2017: R35- NCI Outstanding Investigator Award “Optimizing Allogeneic HSCT”
  • 2024: E. Donnall Thomas Award/Lecture, American Society of Transplantation and Cellular Therapy (ASTCT), San Antonio, Tx
  • 2024: Associate Editor, Williams Textbook of Hematology 11th Edition
  • 2024: Chancellor’s Award for Innovation and Entrepreneurship, Washington University
  • 2024: UCSD Helen Ranney Lecture, Department of Medicine, UCSD Cancer Center
  • 2023: American College of Physicians’ Harriet P. Dustan Award for Science as Related to Medicine
  • 2023: Master Physician Lifetime Achievement Award, Barnes Jewish Hospital, St Louis, MO
  • 2022: Doug Lowry Inaugural Lecture, Wilmot Cancer Center, U of Rochester Med School
  • 2022: Giants of Cancer Care Award for Leukemia Research, Chicago, IL
  • 2022: American-Italian Cancer Foundation’s Prize for Scientific Excellence in Medicine
  • 2021: AACR Co-Chair Annual Meeting, 2021 Program Committee
  • 2021: Danny Thomas Distinguished Lecture, St Jude Children’s Research Hospital
  • 2020: Society of Hematologic Oncology (SOHO) Distinguished Lecture Award Recipient
  • 2019-2018: President, American Society of Blood and Marrow Transplantation
  • 2019: Thomas Buchner Memorial Lecture, Acute Leukemias XVII, Munich, Germany
  • 2019: Distinguished Lecture Award, Society of Hematologic Oncology Annual Meeting
  • 2018: Karl Blume and Gerhard Schmidt Memorial Lecture, City of Hope Cancer Center, Duarte, CA
  • 2018: Teacher of the Year, Department of Medicine, Washington University School of Medicine
  • 2018: Founder, WUGEN Therapeutics, St. Louis, MO
  • 2017-2016: Vice President/President-Elect, American Society of Blood and Marrow Transplantation
  • 2017: Leukemia and Lymphoma Society of American Legacy Award
  • 2016: Washington University School of Medicine 2nd Century Award
  • 2015: Co-founder, Magenta Therapeutics, Cambridge, MA
  • 2014: Recipient of AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
  • 2014: Thomson Reuters list of “Most Influential Scientific Minds”
  • 2014: American Society of Hematology Mentor Award for Clinical Investigation
  • 2013: Daniel P. Schuster Distinguished Translational Investigator Award, Washington University
  • 2013: Member, Association of American Physicians (AAP)
  • 2010: Recipient, Virginia E. and Samuel J. Golman Endowed Professorship in Medicine
  • 2010: Washington University Divisions of Hematology and Oncology “Teacher of the Year”
  • 2008: “Great Teacher” Lecture NIH
  • 2001: ISHAGE Meeting, First prize, Scientific Merit: “Control of GvHD using genetically modified T cells”
  • 1989: Junior Faculty Research Award, American Cancer Society
  • 1992: Bauman Award – Teacher of the Year, Internal Medicine, University of Rochester
  • 1997: Recipient, Lewis T. and Rosalind B. Apple Chair in Oncology
  • 1996: Elected, American Society of Clinical Investigation (ASCI)
  • 1986: Special Fellow, Leukemia Society of America
  • 1980: Alpha Omega Alpha, University of Rochester
  • 1973: BA, Magna Cum Laude, Honors in Biology, Williams College